fbpx

Covaxin gets WHO’s emergency use nod

  • IASbaba
  • November 5, 2021
  • 0
UPSC Articles
Print Friendly, PDF & Email

Covaxin gets WHO’s emergency use nod

Part of: Prelims and GS II – Health

Context India’s first indigenous COVID-19 vaccine, Bharat Biotech’s Covaxin, was granted Emergency Use Listing (EUL) by the World Health Organization (WHO).

What is Covaxin?

  • Covaxin is a whole virion-inactivated vaccine against SARS-CoV-2, developed in partnership with the Indian Council of Medical Research and the National Institute of Virology, Pune. 
  • It has been granted EUL for use in persons 18 years and above, over two doses spaced four weeks apart.
  • It has been formulated to enable shipping and long-term storage at 2-8ºC. 
  • It is also formulated to adhere to a multi-dose vial policy, thereby reducing open vial wastage, saving money to procurement agencies and governments.

Key takeaways 

  • The EUL is a prerequisite for the COVAX initiative in vaccine supply, and allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.
  • With validation from WHO, countries can now expedite their regulatory approval processes to import and administer Covaxin. 
  • UNICEF, Pan-American Health Organization (PAHO), GAVI COVAX facility, will be able to procure Covaxin for distribution to countries worldwide
  • The move is expected to ease international travel for Indians who have opted for the vaccine 

For a dedicated peer group, Motivation & Quick updates, Join our official telegram channel – https://t.me/IASbabaOfficialAccount

Search now.....